Name: Tarsus Pharmaceuticals, Inc. (TARS) Financial Statements
Creator: FinSpry

Tarsus Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Tarsus Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	182.95	17.45	25.82	57.03	0.00
Cost of Revenue	12.83	51.91	43.58	2.08	18.83
Gross Profit	170.13	-34.46	-17.76	54.95	-18.83
Operating Expenses
Research & Development	53.39	50.31	42.62	41.71	0.00
Selling, General & Administrative	237.31	108.70	44.95	25.40	8.17
Operating Expenses	290.70	108.70	44.95	67.11	8.17
Operating Income	-120.57	-143.16	-62.71	-12.16	-27.00
Other Income/Expense
Interest Income	15.01	10.34	3.50	0.04	0.19
Interest Expense	7.45	-3.35	-2.20	0.00	0.00
Other Income/Expense	-2.15	-0.10	0.09	-1.65	0.00
Income
Income Before Tax	-115.55	-135.89	-62.10	-13.77	-26.81
Income Tax Expense	0.00	-4.40	0.00	0.06	0.00
Net Income	-115.55	-135.89	-62.09	-13.83	-26.81
Net Income - Continuous Operations	-115.55	-135.89	-62.09	-13.83	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-106.88	-142.28	-62.39	-13.46	-26.90
EBIT	-108.11	-143.16	-62.71	-13.77	-27.00
Depreciation & Amortization	1.23	0.88	0.33	0.31	0.10
Earnings Per Share
Basic EPS	-3.00	-5.00	-3.00	-1.00	-4.00
Diluted EPS	-3.00	-5.00	-3.00	-1.00	-4.00
Basic Shares Outstanding	37.60	29.38	24.62	20.55	6.21
Diluted Shares Outstanding	37.60	29.38	24.62	20.55	6.21